Results 81 to 90 of about 17,802 (177)

The Effects of the S1P Receptor Agonist Fingolimod (FTY720) on Central and Peripheral Myelin in Twitcher Mice

Biomedicines
Krabbe’s disease (KD) is caused by mutations in the lysosomal enzyme galactocerebrosidase and is associated with psychosine toxicity. The sphingosine 1-phosphate receptor (S1PR) agonist fingolimod (FTY720) attenuates psychosine-induced cell death of ...
Sibylle Béchet, Kumlesh K. Dev
doaj   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, Volume 100, Issue 4, Page 788-792, October 2026.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

Fingolimod potentiates minocycline against multidrug-resistant Elizabethkingia

Frontiers in Cellular and Infection Microbiology
ObjectivesElizabethkingia spp. are intrinsically resistant to multiple antimicrobial classes and are emerging nosocomial pathogens. This study evaluated the antibacterial activity of fingolimod against Elizabethkingia and its interaction with minocycline.
Jie Sun, Qiang Feng, Can Yang, Yulong Zong, Rongliang Gao, Li Shen, Fangyou Yu, Yongpeng Shang   +7 more
doaj   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner. [PDF]

, 2020
The brain-derived neurotrophic factor (BDNF) plays crucial roles in both the developing and mature brain. Moreover, alterations in BDNF levels are correlated with the cognitive impairment observed in several neurological diseases.
Nicoletta Landsberger, Landsberger, Nicoletta, Marta Zagrebelsky, Frasca, Angelisa, Abhisarika Patnaik, Spiombi, Eleonora, Zagrebelsky, Marta, Eleonora Spiombi, Patnaik, Abhisarika, Korte, Martin, Angelisa Frasca, Martin Korte   +11 more
core   +1 more source

Initial OX40–OX40L Signaling Promotes a Skin‐Resident Memory T‐Cell Reservoir in Atopic Dermatitis

Allergy, EarlyView.
Takayoshi Komatsu‐Fujii, Ryota Asahina, Tatsuya Hasegawa, Satoshi Nakamizo, Saeko Nakajima, Toshiaki Kogame, Kenji Kabashima   +6 more
wiley   +1 more source

Fingolimod w leczeniu stwardnienia rozsianego

, 2010
W chwili obecnej leczenie immunomodulujące stwardnienia rozsianego (łac. sclerosis multiplex, SM) polega na podawaniu leków w postaci iniekcji podskórnych, domięśniowych bądź dożylnych.
Andrzej Głąbiński, Paweł Gierach, Marek Juszczak   +2 more
core  

The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives. [PDF]

, 2018
The immunomodulatory drug fingolimod (FTY720, Gilenya(R)) was approved for oral treatment of relapsing-remitting multiple sclerosis, due to its impressive efficacy and good tolerability. Pharmacologically, it acts as an unselective agonist of sphingosine
Zangemeister-Wittke, Uwe, Uwe Zangemeister-Wittke, Huwiler, Andrea, Andrea Huwiler   +3 more
core   +2 more sources

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis

, 2015
Alberto Gajofatto,1,2 Marco Turatti,2 Salvatore Monaco,1,2 Maria Donata Benedetti2 1Department of Neurological, Biomedical and Movement Sciences, University of Verona, Verona, Italy; 2Division of Neurology B, Verona University Hospital, Verona, 
Gajofatto A, Turatti M, Monaco S, Benedetti MD   +3 more
core  

Feasibility of adding fingolimod to radiation to reduce lymphopenia in rodents and glioma patients

Academia Oncology
Introduction: Severe and long-lasting lymphopenia occurs in 40% of patients with malignant gliomas and is associated with inferior survival.
Anna F. Piotrowski, Dvone C. Jackson, Thomas R. Nirschl, Esteban Velarde, John Wong, Charles G. Drake, Xiaobu Ye, Stuart A. Grossman   +7 more
doaj   +1 more source